向明，女，教授，博士研究生导师。
中国药理学会理事，中国抗炎免疫药理学会委员，湖北省药理学会常务理事，武汉市医学会常务理事，世界中医药免疫专业委员会常务理事。
研究方向：抗炎免疫药理学，主要包括：免疫细胞代谢调控功能机制以及慢性代谢性疾病中神经免疫代谢互作机制；肿瘤免疫治疗及机制；抗肿瘤药物耐受和免疫抑制剂不良反应标志物发现及确定。
科研经历：
2010 年赴美国佐治亚医学院从事抗炎免疫抑制剂药理作用研究。
2004 年至2005年赴德国海德堡大学从事抗HCV感染基因疫苗及树突状细胞分化及功能研究。
1997 年至 1999 年赴意大利 CATANIA 大学从事自身免疫病发病和细胞因子抗体的作用及机制研究。
联系方式：xiangming@tjmu.edu.cn
发表文章：
1.Tian C, Huang R,Xiang M*. SIRT1: Harnessing multiple pathways to hinder NAFLD. Pharmacol Res. 2024 May;203:107155. doi: 10.1016/j.phrs.2024.107155.(* correspondence author)
2.Li SL, Zhou H, Liu J, Yang J, Jiang L, Yuan HM, Wang MH, Yang KS,Xiang M*. Restoration of HMGCS2-mediated ketogenesis alleviates tacrolimus-induced hepatic lipid metabolism disorder. Acta Pharmacol Sin. 2024 May 17. doi: 10.1038/s41401-024-01300-0.
3.Li S, Yuan H, Yang K, Li Q,Xiang M*. Pancreatic sympathetic innervation disturbance in type 1 diabetes. Clin Immunol. 2023 May;250:109319. doi: 10.1016/j.clim.2023.109319.
4.Tian C, Yuan H, Lu Y, He H, Li Q, Li S, Yang J, Wang M, Xu R, Liu Q,Xiang M*. CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport. Oncoimmunology. 2023 Apr 19;12(1):2204015. doi: 10.1080/2162402X.2023.2204015.
5.Yang J, He J, Feng Y,Xiang M*. Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling. Front Immunol. 2023 May 17;14:1166440. doi: 10.3389/fimmu.2023.1166440.
6.Yang J, Li S, He J, Xu Q, Xie M, Yang C, Wang H, Zhang Y, Wan Q,Xiang M*. Dual role of PID1 in regulating apoptosis induced by distinct anticancer-agents through AKT/Raf-1-dependent pathway in hepatocellular carcinoma. Cell Death Discov. 2023 Apr 28;9(1):139. doi: 10.1038/s41420-023-01405-1.
7.Li Q, He J, Li S, Tian C, Yang J, Yuan H, Lu Y, Fagone P, Nicoletti F,Xiang M*. The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway. Clin Immunol. 2023 Mar;248:109217. doi: 10.1016/j.clim.2022.109217.
8.Huang R, Wang B, He J, Zhang Z, Xie R, Li S, Li Q, Tian C, Tuo Y, Zheng R, Chen W,Xiang M*. Lian-Qu formula treats metabolic syndrome via reducing fat synthesis, insulin resistance and inflammation. J Ethnopharmacol. 2023 Apr 24;306:116060. doi: 10.1016/j.jep.2022.116060.
9.Yang K, Tian C, Zhang C,Xiang M*. The Controversial Role of IL-33 in Lung Cancer.Front Immunol. 2022;13:897356. 2022 May 12. doi:10.3389/fimmu.2022.897356.
10.Lu Y#, Zhang P#, Chen H, Tong Q, Wang J, Li Q, Tian C, Yang J, Li S, Zhang Z, Yuan H,Xiang M*. Cytochalasin Q exerts anti-melanoma effect by inhibiting creatine kinase B. Toxicol Appl Pharmacol.2022 Apr 15;441:115971. doi: 10.1016/j.taap.2022.115971.
11.Xiang M*, Liu T, Tian C, Ma K, Gou J, Huang R, Li S, Li Q, Xu C, Li L, Lee CH, Zhang Y. Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway. Pharmacol Res. 2022 Mar;177:106092. doi: 10.1016/j.phrs.2022.106092.
12.Li S, Zhou H, Xie M, Zhang Z, Gou J, Yang J, Tian C, Ma K, Wang CY, Lu Y, Li Q, Peng W,Xiang M*. Regenerating islet-derived protein 3 gamma (Reg3g) ameliorates tacrolimus-induced pancreatic β-cell dysfunction in mice by restoring mitochondrial function. Br J Pharmacol. 2022 Jan 20. doi: 10.1111/bph.15803.
13.Li Q,Xiang M*. Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy. Acta Pharmacol Sin. 2021 Sep 24. doi: 10.1038/s41401-021-00776-4.
14.Tian C,Xiang M*.Therapeuticagents against COVID-19 withclinicalevidence.Curr Pharm Des.2021, Jan 14;27:1-10.doi: 10.2174/1381612827666210114150951.
15. Tuo Y, Tian C, Lu L,Xiang M*.The paradoxical role of methionine enkephalin in tumor responses. Eur J Pharmacol. 2020 Sep 5;882:173253. doi: 10.1016/j.ejphar.2020.173253.
16.Tuo Y, Zhang Z, Tian C, Hu Q, Xie R, Yang J, Zhou H, Lu L,Xiang M*. Anti-inflammatory and metabolic reprogramming effects of MENK produce antitumor response in CT26 tumor-bearing mice. J Leukoc Biol. 2020 Jul;108(1):215-228. doi: 10.1002/JLB.3MA0120-578R.
17.Tian C, Tuo YL, Lu Y, Xu CR,Xiang M*. The Role of CARD9 in Metabolic Diseases. Curr Med Sci. 2020 Apr;40(2):199-205. doi: 10.1007/s11596-020-2166-4.
18.Li S, Qian Y, Xie R, Li Y, Jia Z, Zhang Z, Huang R, Tuo L, Quan Y, Yu Z, Liu J,Xiang M*. Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice. J Ethnopharmacol. 2019 Oct 5;242:112029. doi: 10.1016/j.jep.2019.112029.
19.Tuo Y,Xiang M*. mTOR: A double-edged sword for diabetes. J Leukoc Biol. 2019 Aug;106(2):385-395. doi: 10.1002/JLB.3MR0317-095RR.
20.Qian Y, Huang R, Li S, Xie R, Qian B, Zhang Z, Li L, Wang B, Tian C, Yang J,Xiang M*.Ginsenoside Rh2 reverses cyclophosphamide-induced immune deficiency by regulating fatty acid metabolism. J Leukoc Biol. 2019 Jun 18. doi: 10.1002/JLB.2A0419-117R.
21.Zhou Z, Chen H, Xie R, Wang H, Li S, Xu Q, Xu N, Cheng Q, Qian Y, Huang R, Shao Z,Xiang M*. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer, Mol Oncol, 2019 Apr;13(4):873-893.
22.Tuo Y,Xiang M*. mTOR: A double-edged sword for diabetes. J Leukoc Biol.2018 Mar 26. doi: 10.1002/JLB.3MR0317-095RR.
23.Cao H, Li S, Xie R, Xu N, Qian Y, Chen H, Hu Q, Quan Y, Yu Z, Liu J,Xiang M*. Exploring the Mechanism of Dangguiliuhuang Decoction Against Hepatic Fibrosis by Network Pharmacology and Experimental Validation. Front Pharmacol. 2018 Mar 5;9:187. doi: 10.3389/fphar.2018.00187.
24.Liu X, Zhou Z, Cheng Q, Wang H, Cao H, Xu Q, Tuo Y, Jiang L, Zou Y, Ren H,Xiang M*.Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.Cell Death Dis. 2017 Sep 7;8(9):e3033. doi: 10.1038/cddis.2017.424.
25.Cao H, Tuo L, Tuo Y, Xia Z, Fu R, Liu Y, Quan Y, Liu J, Yu Z,Xiang M*. Immune and Metabolic Regulation Mechanism of Dangguiliuhuang Decoction against Insulin Resistance and Hepatic Steatosis. Front Pharmacol. 2017 Jul 7;8:445. doi: 10.3389/fphar.2017.00445.
26.Xiang M, Liu T, Tan W, Ren H, Li H, Liu J, Cao H, Cheng Q, Liu X, Zhu H, Tuo Y, Wang J, Zhang Y.Effects of kinsenoside, a potential immunosuppressive drug for autoimmune hepatitis, on DCs-CD8+T cells communication.Hepatology.2016 Dec 64(6):2135-2150. doi: 10.1002/hep.28825.
27.Xia F, Cao H, Du J, Liu X, Liu Y,Xiang M*. Reg3g overexpression promotes β cell regeneration and induces immune tolerance in nonobese-diabetic mouse model. J Leukoc Biol. 2016 Jun; 99(6):1131-40. doi: 10.1189/jlb.3A0815-371RRR.
28.Xu QQ, Fu R, Yin GX, Liu XL, Liu Y,Xiang M*. Microarray-based gene expression profiling reveals genes and pathways involved in the oncogenic function of REG3A on pancreatic cancer cells. Gene.2016 Mar 10; 578(2):263-73. doi: 10.1016/j.gene.2015.12.039.
29.Liu X,Wang J,Wang H,Yin G,Liu Y,Lei X,Xiang M*. REG3A accelerates pancreatic cancer cell growth under IL-6-associated inflammatory condition: Involvement of a REG3A-JAK2/STAT3 positive feedback loop.Cancer Lett.2015 Jun 28; 362(1): 45-60. doi: 10.1016/j.canlet.2015.03.014.
30.Cao H, Lu J, Du J, Xia F, Wei S, Liu X, Liu T, Liu Y, Xiang M*.TAK1 inhibition prevents the development of autoimmune diabetes in NOD mice.Sci Rep. 2015 Oct 13;5:14593. doi: 10.1038/srep14593.
31.Wang J,Cao H,Wang H,Yin G,Du J,Xia F,Lu J,Xiang M*. Multiple mechanisms involved in diabetes protection by lipopolysaccharide in non-obese diabetic mice.Toxicol Appl Pharmacol.2015 Jun 15;285 (3):149-58. doi:1016/j.taap. 2015. 04. 006.
32.Liu T,Cao H,Ji Y,Pei Y,Yu Z,Quan Y*,Xiang M*. Interaction of dendritic cells and T lymphocytes for the therapeutic effect of Dangguiliuhuang decoction to autoimmune diabetes.Sci Rep.2015 Sep 11; 5:13982. doi: 10.1038/srep13982.
33.Cao H, Ji Y, Li W, Liu Y, Fu R,Xiang M*. Protective Effects of the Total Coumarin Fraction of Urticadentata on Experimental Diabetic Nephropathy In Vitro and In Vivo. Planta Med. 2015 Oct; 81(15):1353-60. doi: 10.1055/s-0035-1557866.
34.Yin G, Du J, Cao H, Liu X, Xu Q,Xiang M*. Reg3g Promotes Pancreatic Carcinogenesis in a Murine Model of Chronic Pancreatitis.Digest Dis Sci. 2015Dec; 60(12):3656-68. doi: 10.1007/s10620-015-3787-5.
35.Wang J, Zhou H, Han Y, Liu X, Wang M, Wang X, Yin G, Li X, Xiang M*.SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer.J Mol Med. 2014 Jul 5; 92(12):1257-69. doi: 10.1007/s00109-014-1184-8.
36.Wang J, Xiang M*. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment? Pharmacotherapy. 2013 May;33(5):515-28. doi: 10.1002/phar.1236.
37.Wang J, Lu J, Lan Y, Zhou H, Li W, Xiang M*. Total coumarins from Urticadentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways. J Ethnopharmacol. 2013 Mar 7;146(1):379-92.
38.Xiang M, Lu J, Zhang C, Lan Y, Zhou H, Li X, Peng W. Identification and quantification of total coumarins from Urticadentata Hand and its roles in promoting immune tolerance via TLR4-mediated dendritic cell immaturation. Biosci.Biotechnol.Biochem. 2013 Jun 23;77(6):1200-6.
39.Xie S,Feng J,Yu C,Li Z,Wu Y,Cao Z,Li W,He X,Xiang M*,Han S. Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilustricostatus.Peptides.2012 Jul;36(1):94-9.
40.Lu J, Zeng Y, Hou W, Zhang S, Li L, Luo X, Xi W, Chen Z,Xiang M*. The soybean peptide aglycin regulates glucose homeostasis in type 2 diabetic mice via IR/IRS1 pathway. J NutrBiochem. 2012; 23(11):1449-57.
41.Xiang M, Zhang S, Lu J, Li L, Hou W, Xie M, Zeng Y. Antilithic effects ofextracts from Urticadentata hand on calcium oxalate urinary stones in rats. J HuazhongUnivSci Technol. 2011; 31(5): 673-677.
42.Luo X, Li L, Zhang S, Lu J, Zeng Y, Zhang H,Xiang M*. Therapeutic effects of total coumarins from Urticadentata Hand on collagen-induced arthritis in Balb/c mice. J Ethnopharmacol. 2011; 138(2): 523-9.
43.Hou W, Xie S,Wang HJ, Su YY, Lu JL, Li LL, Zhang SS,Xiang M*. Intramuscular delivery of a naked DNA plasmid encoding proinsulin and pancreatic regenerating III protein ameliorates type 1 diabetes mellitus. Pharmacological Research. 2011; 63（4）: 320-327.
44.Hou W, Su ZQ, Pi HF, Yao GM, Zhang P, Luo X, Xie SN,Xiang M*. Immunosuppressive constituents from Urticadentata Hand. J Asian Nat Prod Res. 2010; 12(8): 707-13.
45.Xiang M, Hou W, Xie S, Zhang WD, Wang X. Immunosuppressive effects of an ethyl acetate extract from Urticadentata Hand on skin allograft rejection. J Ethnopharmacol. 2009; 126: 57-63.
46.Zhang C, Zou X, Guan L, Xu J,Xiang M*. Prevention of Type 1 Diabetes by Immature Dendritic Cells Treated with an Ethanol Extract of Paecilomyceshepiali Chen Mycelium. Methods Find ExpClinPharmacol. 2008; 30(6): 421-429.
47.Zou X,Zhao Z, Wang Y, Su Z,Xiang M*. Diabetogenic T cells induce autoimmune diabetes in BALB/c mice. Chin Med Sci J. 2008; 23(2):88-94.
48.Xiang M, Zou X, Zhang C, Zhao Z,Xu J. Insulin administration confers diabetes-preventive properties to NOD mice derived dendritic cells. ImmunopharmacolImmunotoxicol. 2007; 29(3-4): 451-64.
49.Zhang C, Zou X,Xiang M*. Immune tolerance induced by adoptive transfer of DCs in IDDM murine model. ActaPharmacologicaSinica. 2007; 28(1): 98-104
50.Xiang M, Eisenbach C, Lupu C, Ernst E, Stremmel W，Encke J. Induction of antigen-specific immune responses in vivo after vaccination with dendritic cells transduced with adenoviral vectors encoding hepatitis C virus NS3. Viral Immunology. 2006; 19(2): 210-219.
51.Xiang M, Zhang C, Zou X, Cai X, Peng J. Roles of dendritic cells and regulatory T cells in autoantigen-induced urine immune tolerance model. World Chinese Journal of Digestive. 2006; 14(7): 687-692.
52.Xiang M, Eisenbach C, Ernst E, Weigand K, Stremmel W, Encke J. Humoral and cellular immune responses elicited by immunization with genetically modified dendritic cells expressing HCVNS3. Hepatology. 2005; 42 (4) Suppl.1:248A
53.Nicoletti F, Zaccone P,Xiang M, Magro G, Di Mauro M, Di Marco R, Garotta G, Meroni P. Essential pathogenetic role for interferon (IFN-)gamma in concanavalin -induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein. Cytokine. 2000; 12(4): 315-23.
54.Nicoletti F, Di Marco R, Zaccone P,Xiang M, Magro G, Grasso S, Morrone S, Santoni A, Shoenfeld Y, Garotta G, Meroni P. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice. Eur J Immunol. 2000; 30(2): 438-47.
55.Di Marco R,Xiang M, Zaccone P, Leonardi C, Franco S, Meroni P, Nicoletti F. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity. 1999; 31(2): 75-83.
56.Xiang M, Zaccone P, Di Marco R, Harris R, Magro G, Di Mauro M, Meroni PL, Garotta G, Nicoletti F. Failure of exogenously administered interferon-gamma or blockage of endogenous interleukin-4 with specific inhibitors to augment the incidence of autoimmune diabetes in male NOD mice. Autoimmunity. 1999; 30(2):71-80.
57.Xiang M, Zaccone P, Di Marco R, Magro G, Di Mauro M, Beltrami B, Meroni PL, Nicoletti F. Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice. Eur J Pharmacol. 1999; 367(2-3): 399-404.
发明专利：
1.发明专利 “从红活麻中提取的新型免疫抑制剂及提取方法和应用”（专利号：ZL 200910062442.8，第一人）
2.发明专利“2H-1-苯并吡喃-2-酮在制备药物中的应用”（专利号: ZL 201510414085.2，第一人）
3.发明专利“具有抗自身免疫性肝炎作用活性的化合物及其制备方法”（专利号: ZL 201610685644.8，第二人）
4.发明专利“2H-1-苯并吡喃-2-酮在制备抑制淋巴细胞增殖药物中的应用”（专利号: ZL 201711092697X，第一人）
5.发明专利“METHOD FOR TREATING LIVER DISEASE WITH KINSENOSIDE”（专利号：US11154567B2，第二人）
6.发明专利“一种治疗代谢综合症的药物”（专利号：ZL 202010068908.1,第一人）
学术奖励：
1.“民族药红活麻的物质基础及药效学研究和应用”荣获2014年湖北省科技进步奖贰等奖。（第一完成人）
2.“民族药红活麻的物质基础及药效学研究”荣获2014年武汉市科技进步奖叁等奖。（第一完成人）
3.“复方碳酸钙颗粒的关键技术创新及产业化”荣获2021年湖北省科技进步贰等奖。（第一完成人）
承担在研课题：
2024-2027：国家自然科学基金“胰岛交感神经失调致巨噬细胞功能转变促T1D的作用机制研究”No82371824
2021-2024：国家自然科学基金“肥胖基因PID1调控肝癌MDSCs脂质代谢和功能重塑的机制研究” No 82071749
2021-2023：湖北省重点研发计划“高血脂干扰M1/M2平衡促进肺纤维化发展的机制及抗炎调脂候选药物治疗作用研究”No2020BHB019
编写教材：
1.向明主编《药物毒理学》第五版 2019年中国医药科技出版社
2.向明主编《药物毒理学》(案例版) 第一版 2024年科学出版社
3.向明副主编《临床药物治疗学》第五版 2022年人民卫生出版社
4.向明副主编《药学导论》第一版 2017年科学出版社
5.向明参编《药理学》第九版2018年人民卫生出版社
6.向明参编《药理学》第五版2019年中国医药科技出版社
7.向明主编《临床药物治疗学图表解》2008年人民卫生出版社
8.向明主译《Lippincott’s图解药理学》2006年中国医药科技出版社
9.向明副主译《面向未来的医学教育》2023年人民卫生出版社
